Investment analysts at Bank of America started coverage on shares of resTORbio (NASDAQ:TORC) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.
Separately, Evercore ISI started coverage on resTORbio in a research report on Tuesday. They issued an “outperform” rating for the company.
Shares of resTORbio (NASDAQ TORC) opened at $18.76 on Tuesday. resTORbio has a 12-month low of $15.18 and a 12-month high of $20.50.
In other news, major shareholder Puretech Health Llc bought 233,333 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was bought at an average price of $15.00 per share, for a total transaction of $3,499,995.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink
. Also, Director Orbimed Advisors Llc bought 533,333 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was purchased at an average price of $15.00 per share, with a total value of $7,999,995.00. The disclosure for this purchase can be found here
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/20/restorbio-torc-now-covered-by-bank-of-america.html.
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.